916649-51-9

Upstream product

• 112-29-8 1-bromo dodecane 
• 645403-10-7 5-O-benzyl-2,3-dideoxy-L-threo-hexono-1,4-lactone 
• 916986-45-3 7-O-benzoyl-5-O-benzyl-2,3-dideoxy-D-xylo-heptono-1,4-lactone 
• 645402-96-6 6-aldehydo-5-O-benzyl-2,3-dideoxy-L-threo-hexono-1,4-lactone 
• 645403-01-6 5-O-benzyl-2,3-dideoxy-D-xylo-heptono-1,4-lactone 
• 645402-98-8 5-O-benzoyl-3-O-benzyl-α-D-xylofuranose 
• 645403-00-5 methyl 7-O-benzoyl-5-O-benzoyl-2,3-dideoxy-D-xylo-heptonate 
• 645402-99-9 methyl 7-O-benzoyl-5-O-benzoyl-2,3-dideoxy-D-xylo-hept-2-enoate 
• 645402-97-7 5-O-benzoyl-3-O-benzyl-1,2-O-cyclohexylidene-α-D-xylofuranose 

Relevant academic research and scientific papers

Enantiodivergent synthesis of muricatacin related lactones from d-xylose based on the latent symmetry concept: preparation of two?novel cytotoxic (+)- and (-)-muricatacin 7-oxa analogs

Enantiodivergent formal synthesis of (+)- and (-)-muricatacins from d-xylose has been accomplished through utilization of the?latent plane of symmetry present in the starting monosaccharide. This approach was extended to the preparation of two novel (+)-

Synthesis and?antitumour activity of?new muricatacin and?goniofufurone analogues

A divergent approach to the 7-oxa (-)-muricatacin analogue 2, the corresponding (+)-enantiomer ent-2 and the furanolactone 3 is reported starting from d-xylose. The resulting lactones have shown a potent and selective in vitro cytotoxicity against certain